

Support for Key Opinion Leaders - Calendar Year 2022

Location	Name	Purpose / Project supported	Programme	Amount
UK	David Parr - University hospitals Coventry	MPH-966 Ad Board Sept 2022	Alvelestat (MPH-966)	£1,425
UK	Ken Chapman - Inspiration Research	MPH-966 Ad Board Sept 2022	Alvelestat (MPH-966)	\$1,138

Support for Medical Affairs and Scientific Meetings - Calendar Year 2022

Location	Name	Purpose / Project supported	Programme	Amount
FR	Hopital Necker	Medical Grant	Setrusumab (MPH-804)	€ 1,800
	ECTS / ISCBH	Medical Grant	Setrusumab (MPH-804)	£7,500
	ECTS / ISCBH	Medical Grant	Setrusumab (MPH-804)	€ 45,000

Location	Name	Purpose / Project supported	Programme	Amount
	Brittle Bone Society	Patient Group	Setrusumab (MPH-804)	£15,000
	Fundacion AHUCE	Patient Group	Setrusumab (MPH-804)	€ 5,000
	OI Foundation	Patient Group	Setrusumab (MPH-804)	\$12,500
	Osteogenesis Imperfecta Federation Europe	Patient Group	Setrusumab (MPH-804)	€ 30,000
	Zelfhulp Osteogenesis Imperfecta	Patient Group	Setrusumab (MPH-804)	€ 10,000

Location	Name	Purpose / Project supported	Programme	Amount
UK	Robert Stockley - University hospitals birmingham	Key opinion leader / consultant	Alvelestat (MPH-966)	£200
UK	David Parr - University hospitals Coventry	Key opinion leader / consultant	Alvelestat (MPH-966)	£4,175
UK	Nick Bishop - The University of Sheffield	Key opinion leader / consultant	Setrusumab (MPH-804)	£3,570
UK	Ken Chapman - Inspiration Research	MPH-966 Ad Board Feb 2022	Alvelestat (MPH-966)	\$1,050
UK	Peter Zioupos - Cranfield University	Key opinion leader / consultant	Setrusumab (MPH-804)	£867
UK	Target to Treatment Consultancy Ltd	Key opinion leader / consultant	Alvelestat (MPH-966)	£2,031